Navigation Links
Ironridge Global Partners, LLC Successfully Concludes Equity Financings of ULURU Inc.
Date:8/15/2013

San Francisco (PRWEB) August 15, 2013

Ironridge Global Partners, LLC, an institutional investor making direct equity investments in micro-cap public companies, and its affiliates successfully completed financing transactions with specialty pharmaceutical company ULURU Inc., that were entered into on September 15, 2011, under which Ironridge Global agreed to purchase common and preferred stock. At the election of the company, all outstanding preferred stock was redeemed and all outstanding notes were satisfied in full. Ironridge Global continues to be a common stockholder of the company. ULURU stock closed up today at $0.52 per share.

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex® Aggregate technology and OraDisc™ transmucosal delivery system. For further information about ULURU Inc., please visit its website at http://www.uluruinc.com.

About Ironridge Global Partners®

Ironridge Global Partners, LLC is an institutional investor, making direct equity investments in micro-cap public companies. Its Liability for Equity (LIFE™) program allows public companies to satisfy trade payables, debts and other liabilities in exchange for unregistered common stock utilizing a Section 3(a)(10) fairness hearing. Ironridge Global is the industry leader in this innovative financing structure, which substantially reduces the transactional costs and time necessary to complete a deal. The fund has entered into more than 50 equity financing transactions since 2011, ranging from under a quarter million to over $15 million each. Ironridge Global seeks to be a long-term financial partner, assisting public companies in financing growth and expansion by supplying innovative funding solutions and flexible capital. For more information on Ironridge Global Partners, please visit http://www.IronridgeGlobal.com.

Contact:
Keith Coulston
Ironridge Global Partners, LLC
415-658-9551

Read the full story at http://www.prweb.com/releases/2013/8/prweb11033545.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
2. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
3. Global Cleantech Cluster Association Names New York City Startup Rentricity to Global Top 10 List
4. StemCyte Adds World Class Talent to its North America and Global Operations
5. Sequenom Named to NASDAQ Global Select Market
6. Synthetic Biology: Emerging Global Markets
7. MacroGenics Receives Milestone Payment as Part of Its Global DART™ Alliance with Boehringer Ingelheim
8. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
9. Hemodialysis Machine Industry 2012 Global & China Market Research Report - ReportsnReports
10. MarketsandMarkets: Global Seed Treatment Market worth $3430.3 Million by 2016
11. Accuray Surpasses 600 Installations Globally
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... MOSCOW , March 27, 2017 Infectex Ltd., a Russian ... Phase 2b-3 clinical study of SQ109 added to the standard drug therapy regimen in ... by scientists at Sequella, Inc. ( USA ) and the US National ... ... Maxwell Biotech Venture Fund Logo ...
(Date:3/27/2017)... -- Perthera,s Chief Bioinformatics Officer and research faculty member at ... will be speaking at the American Medical Informatics Association ... 2017, she will be speaking on the topic of ... Care" (from 10:30 a.m. – 12:00 p.m. PST) and ... participant in the "Making Precision Oncology Data More Usable ...
(Date:3/27/2017)... ... March 27, 2017 , ... PMG Research is pleased to announce ... by The Conference Forum in Boston on April 3-4, 2017. The CTC conference focuses ... trial outcomes and bring them closer to the patient. Clinical Trial Collaborations also will ...
(Date:3/27/2017)... 27, 2017  Trovagene, Inc. (NASDAQ: TROV), a precision ... Officer, Bill Welch , will be presenting at ... 9:00 AM EDT at the Essex House in ... Chief Scientific Officer, Mark Erlander , Ph.D., will ... conference.   The presentation will be webcast live ...
Breaking Biology Technology:
(Date:2/26/2017)... -- Securus Technologies, a leading provider of civil and ... corrections and monitoring, announces the appointment of a ... often, too many offenders return to jail or ... to tackle this ongoing problem and improve the ... significant steps are underway, Securus continues to invest ...
(Date:2/22/2017)... 2017 With the biometrics market to ... four technologies that innovative and agile startups must ... in the changing competitive landscape: multifactor authentication (MFA), ... "Companies can no longer afford to ... Dimitrios Pavlakis , Industry Analyst at ABI ...
(Date:2/21/2017)... LONDON , February 21, 2017 ... um 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr ... es einige Hindernisse zu überwinden gilt, um diese Prognose ... ... unter anderem die Mobilisierung der finanziellen Mittel für die ...
Breaking Biology News(10 mins):